Neurocrine Biosciences shares gain on positive phase 2 trial
Shares of Neurocrine Biosciences, Inc. (Nasdaq:NBIX) leaped in pre-market trading this morning after the biopharmaceutical company focused on neurological and endocrine diseases and disorders reported positive safety results late Tuesday night from its third Phase II clinical trial in patients with endometriosis.
Shares jumped 19%, or $1.01, to $6.25 in pre-market trading. For detailed price information and news stories on Neurocrine Biosciences, click NBIX.
